| Recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With NCT06696755 | AbbVie | Phase 2 |
| Recruiting | Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. NCT07494305 | LB Pharmaceuticals Inc. | Phase 2 |
| Recruiting | Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder NCT07213466 | Mayo Clinic | Phase 4 |
| Recruiting | An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With NCT07288320 | Neurocrine Biosciences | Phase 2 |
| Enrolling By Invitation | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) NCT07217860 | Xenon Pharmaceuticals Inc. | Phase 3 |
| Recruiting | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disord NCT07172516 | Xenon Pharmaceuticals Inc. | Phase 3 |
| Completed | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder NCT07116694 | BioXcel Therapeutics Inc | Phase 2 |
| Not Yet Recruiting | SYNCED - SYNChronized Eating in Bipolar Depression Study NCT06560957 | University of Ottawa | N/A |
| Recruiting | LHC-CIDI-5 in Hong Kong NCT06804525 | The University of Hong Kong | — |
| Completed | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipo NCT06605599 | AbbVie | Phase 2 |
| Active Not Recruiting | Sequential Multiple Assignment Randomized Trial for Bipolar Depression NCT06433635 | Massachusetts General Hospital | Phase 4 |
| Enrolling By Invitation | Open Label Extension Study of NCT06221852 NCT06558201 | Mclean Hospital | N/A |
| Completed | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions NCT06494397 | Vanda Pharmaceuticals | Phase 1 |
| Completed | Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants Wi NCT06256367 | AbbVie | — |
| Completed | A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020) NCT06273774 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder NCT06221852 | Mclean Hospital | N/A |
| Recruiting | Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder NCT05837104 | Mclean Hospital | Phase 2 |
| Completed | Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder NCT05956483 | AbbVie | — |
| Recruiting | NMDA Receptor Modulation for the Treatment of Bipolar I Disorder NCT05977023 | China Medical University Hospital | Phase 2 |
| Suspended | CBT for Problematic Impulsive Behaviours in Bipolar Disorder: A Case Series / CBT-PIB NCT06129500 | University of Exeter | N/A |
| Completed | A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion NCT06372210 | Otsuka Pharmaceutical Development & Commercialization, Inc. | N/A |
| Recruiting | Safety and Tolerability of Open-Labeled Iloperidone in Adolescents NCT05648591 | Vanda Pharmaceuticals | Phase 4 |
| Completed | A Study of Spoken Language in Mania NCT05956340 | Mayo Clinic | N/A |
| Completed | iTBS in Bipolar I Depression NCT05375214 | Johns Hopkins University | N/A |
| Unknown | Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness NCT05705063 | Stanford University | N/A |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III NCT05658510 | BioXcel Therapeutics Inc | Phase 3 |
| Suspended | Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression NCT05340686 | Region Stockholm | N/A |
| Completed | Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression NCT05339074 | Joshua Rosenblat | Phase 2 |
| Completed | Ketamine for Treatment-Resistant Bipolar Disorder NCT05004896 | Joshua Rosenblat | Phase 2 |
| Recruiting | Children's Bipolar Network Treatment Trial I NCT05427123 | University of California, Los Angeles | — |
| Recruiting | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or NCT05303064 | Alkermes, Inc. | Phase 3 |
| Completed | Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder NCT05340504 | Medical University of South Carolina | Phase 2 |
| Recruiting | Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders NCT05064319 | Medical University of South Carolina | Phase 2 |
| Completed | Obsessions and Suicidality in Youth With Bipolar 1 Disorder NCT05878808 | Cairo University | — |
| Unknown | Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE) NCT04907279 | Otsuka Canada Pharmaceutical Inc. | — |
| Enrolling By Invitation | Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects NCT04987229 | Alkermes, Inc. | Phase 3 |
| Unknown | The Effect of Interpersonal Relationships and Social Rhythm Therapy Individuals With Bipolar Disorder NCT05420792 | Ege University | N/A |
| Completed | Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder NCT04987658 | Alkermes, Inc. | Phase 1 |
| Terminated | Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients NCT04771299 | Lakshmi N Yatham | Phase 3 |
| Unknown | Naturalistic Study of Ketamine in the Treatment of Depression NCT05249309 | Hospital de Clinicas de Porto Alegre | — |
| Recruiting | A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Dep NCT04777357 | AbbVie | Phase 3 |
| Completed | Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated NCT04819776 | Vanda Pharmaceuticals | Phase 3 |
| Completed | Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatm NCT04578756 | AbbVie | Phase 3 |
| Unknown | Emotional Proactive Processing in Bipolar Disorder NCT04561622 | University Hospital, Grenoble | — |
| Completed | Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients NCT04315792 | Jina Pharmaceuticals Inc. | Phase 3 |
| Withdrawn | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder NCT04211428 | ProgenaBiome | — |
| Unknown | Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: Th NCT04209140 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Early Psychosis Intervention - Spreading Evidence-based Treatment NCT03919760 | Centre for Addiction and Mental Health | N/A |
| Completed | Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia NCT04127058 | Vanda Pharmaceuticals | Phase 1 |
| Completed | Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders NCT03943537 | Mclean Hospital | Phase 2 |
| Completed | A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder NCT04030143 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 / Phase 2 |
| Completed | Using Neuroplasticity-Based Computerized Training to Improve Emotion Regulation in Bipolar Disorder (BRAINS) NCT05683431 | Rush University Medical Center | N/A |
| Completed | A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disord NCT03854409 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 |
| Completed | Multicenter, Randomized, Comparative and Prospective Study Evaluating the Impact on the Care Path of an Editor NCT03630822 | Assistance Publique Hopitaux De Marseille | N/A |
| Completed | Efficacy of Convulsive Therapies for Bipolar Depression NCT03641300 | Centre for Addiction and Mental Health | N/A |
| Unknown | Continuous Theta Burst Stimulation as an add-on Treatment for Bipolar Depression NCT03603561 | Universiteit Antwerpen | N/A |
| Active Not Recruiting | ERG Components in Schizophrenia and Bipolar Disorder Type I NCT03788811 | diaMentis Inc. | — |
| Completed | A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic NCT03573297 | AbbVie | Phase 3 |
| Active Not Recruiting | Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression NCT03484494 | Mclean Hospital | N/A |
| Completed | A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar NCT03287869 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years O NCT03292848 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 |
| Completed | Gabapentin for Bipolar & Cannabis Use Disorders NCT03334721 | Medical University of South Carolina | Phase 2 |
| Completed | A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipo NCT03257865 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipol NCT03259555 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Unknown | Financial Incentives to Improve Acceptance of Antipsychotic Injections NCT03192631 | Focus Community Mental Health Team | N/A |
| Completed | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 NCT03201757 | Alkermes, Inc. | Phase 3 |
| Completed | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed Wi NCT03187769 | Alkermes, Inc. | Phase 3 |
| Completed | The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic NCT03156504 | Mayo Clinic | Phase 4 |
| Completed | LiveWell: A Mobile Intervention for Bipolar Disorder NCT03088462 | Northwestern University | N/A |
| Completed | Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System NCT02722967 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| Completed | Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disor NCT02593643 | Sunnybrook Health Sciences Centre | EARLY_Phase 1 |
| Terminated | Ginger.io Behavioral Health Study NCT02491307 | Community Health Center, Inc. | N/A |
| Completed | Lurasidone and Cognition in Bipolar I Disorder NCT02147379 | University of British Columbia | Phase 3 |
| Completed | A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. NCT01986114 | Sumitomo Pharma Co., Ltd. | Phase 3 |
| Completed | Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder NCT01998516 | Medical University Innsbruck | — |
| Completed | Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents NCT01731119 | University of North Carolina, Chapel Hill | Phase 2 |
| Completed | Lifestyle Intervention for Diabetes and Weight Management in Psychosis NCT01828931 | Centre for Addiction and Mental Health | N/A |
| Completed | Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance NCT01567527 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression NCT01655030 | University of Sao Paulo | N/A |
| Unknown | Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients NCT01710163 | University of Sao Paulo | Phase 4 |
| Completed | This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability NCT01575561 | Sumitomo Pharma America, Inc. | Phase 3 |
| Completed | Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 NCT01395992 | Forest Laboratories | Phase 3 |
| Completed | An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest) NCT01765127 | Professor Saad Shakir | — |
| Withdrawn | Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania NCT01495156 | Northwell Health | Phase 4 |
| Completed | Sequential Multiple Assignment Treatment for Bipolar Disorder NCT01588457 | The University of Texas Health Science Center at San Antonio | Phase 4 |
| Completed | Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex NCT01358357 | Sumitomo Pharma America, Inc. | Phase 3 |
| Terminated | Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder. NCT00958633 | University of British Columbia | Phase 3 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Popul NCT01206517 | Organon and Co | Phase 1 |
| Completed | Emotion Regulation Group Therapy for Bipolar Disorder NCT01207505 | Massachusetts General Hospital | N/A |
| Completed | Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder NCT01059539 | Forest Laboratories | Phase 3 |
| Completed | Safety and Efficacy of Cariprazine for Bipolar I Disorder NCT01058668 | Forest Laboratories | Phase 3 |
| Completed | Prevention of Weight Gain in Early Psychoses NCT01075295 | Centre for Addiction and Mental Health | N/A |
| Completed | Study in Adolescents With Schizophrenia or Bipolar Disorder NCT00982020 | Eli Lilly and Company | Phase 4 |
| Terminated | Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients NCT00857818 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Efficacy of Combined Treatment for Young Bipolar I Disorder NCT00976794 | University of Sao Paulo | Phase 4 |
| Completed | Sensoril(Ashwaganhda)for Bipolar Disorder NCT00761761 | University of Pittsburgh | Phase 3 |
| Completed | Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study NCT00746343 | University of Pittsburgh | N/A |
| Completed | Staccato Loxapine in Agitated Patients With Bipolar Disorder NCT00721955 | Alexza Pharmaceuticals, Inc. | Phase 3 |
| Completed | Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain NCT00709202 | Nathan Kline Institute for Psychiatric Research | Phase 2 |
| Completed | Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed NCT00618748 | Eli Lilly and Company | Phase 3 |
| Completed | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole i NCT00606281 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Co NCT00606229 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Co NCT00606320 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Ar NCT00606177 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions NCT01570894 | Roxane Laboratories | N/A |
| Completed | Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions NCT01570959 | Roxane Laboratories | N/A |
| Unknown | Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder NCT00608075 | University of Cincinnati | Phase 4 |
| Completed | A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Pa NCT00402324 | Eli Lilly and Company | Phase 4 |
| Completed | The Young Adult and Pediatric Bipolar Study NCT00350857 | Validus Pharmaceuticals | Phase 4 |
| Completed | Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disord NCT01825837 | Bial - Portela C S.A. | Phase 2 |
| Terminated | Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I D NCT01824602 | Bial - Portela C S.A. | Phase 2 |
| Completed | Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With NCT00114686 | AstraZeneca | Phase 3 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I D NCT01822678 | Bial - Portela C S.A. | Phase 2 |
| Completed | A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescent NCT00232414 | University of Cincinnati | Phase 3 |
| Completed | A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents NCT00195780 | Abbott | Phase 3 |
| Completed | PK Effects of Bifeprunox & Valproate in Bipolar I NCT00141505 | Solvay Pharmaceuticals | Phase 2 |
| Completed | An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Tr NCT00238485 | Novartis | Phase 3 |
| Completed | An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Man NCT00228059 | Novartis | Phase 3 |
| Completed | L-Carnosine for Bipolar I Disorder NCT00177463 | University of Pittsburgh | N/A |
| Completed | Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disord NCT00227305 | AstraZeneca | Phase 3 |
| Completed | A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode NCT00094432 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder NCT00107731 | AstraZeneca | Phase 3 |
| Completed | Risperdal Consta for Bipolar Disorder NCT00177164 | University of Pittsburgh | Phase 3 |
| Completed | Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode NCT01977300 | University of British Columbia | Phase 3 |
| Completed | Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder NCT00046384 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder NCT00178061 | University of Pittsburgh | Phase 4 |